128 results
Page 4 of 7
6-K
EX-99.1
s4002jfs xpdv6ogddd
3 May 21
Current report (foreign)
4:15pm
6-K
EX-99.1
e5464
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
6-K
EX-5.1
2vy0a
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-5.2
69di58bg4o51n9
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-99.1
c9cy0mhy 615b0q90
1 Mar 21
Current report (foreign)
12:00am
424B5
0nyv7b8autv5e
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
l0ffktvl
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
6hm tc5zg
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
2c937nn
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.1
83vvegmntuerhj
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.2
3bj18q7
29 Oct 20
Current report (foreign)
7:05am
S-8
EX-23.2
kzsce mzpaesnp5km8q
30 Jul 20
Registration of securities for employees
8:39am
S-8
EX-5.1
jljhcsuro0
30 Jul 20
Registration of securities for employees
8:39am
6-K
EX-99.2
kyyhv mcp
30 Jul 20
Current report (foreign)
7:36am
424B5
pgi zi2dxr2
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
ge70aiv7
20 Jul 20
from 6-K
9:02am